ALBPS — Biophytis SA Share News
0.000.00%
Last trade - 00:00Brief: Biophytis Begins Regulatory Process For Early Access Authorization For Treatment Of COVID-19
Brief: Biophytis End-June Cash And Cash Equivalents At EUR 19.7 mln
Brief: Biophytis Announces Judgment Of The Paris Court Of Appeal Of 17 Jan 2023 In The Case Between Biophytis And Negma Group Ltd
Brief: Biophytis To Take Measures After Nasdaq Deficiency Notice
Brief: Biophytis: Positive Post-HOC Analysis Of Phase 2-3 COVA Clinical Study
Brief: Biophytis H1 Operating Loss Widens To 11.9 Million Euros
Brief: Biophytis Says No Longer Satisfies Nasdaq Listing Rule 5550(A)(2).
Brief: Paris Court Of Appeal Rules In Favour Of Biophytis In Case Against Negma Group
U.S. STOCKS ON THE MOVE-Biophytis, Gold miners, Imara
Biophytis surges after mid-stage study results for COVID-19 treatment
Brief: Biophytis Says 'Promising' Top Line Results In COVID Study
Brief: Biophytis To Present Development Of Phase 3 Treatment For Sarcopenia
Brief: Biophytis Presents Preclinical Efficacy Data For Sarconeos (Bio101) In Spinal Muscular Atrophy
Brief: Biophytis Presents Sarconeos (BIO101) Development Program In Sarcopenia
Biophytis falls as COVID-19 impacts lead drug clinical program
Brief: Biophytis Appoints Philippe Rousseau As CFO
Biophytis jumps on expanded access for COVID-19 treatment in Brazil
Brief: Biophytis Receives Brazil's Approval For Sarconeos For Hospitalized Covid-19 Patients
Brief: Biophytis To Meet With FDA To Advance Sarconeos Development In Sarcopenia From Phase 2 To Phase 3